ZN-A-1041

DRUG2 trials

Sponsors

Hoffmann-La Roche, Genentech, Inc.

Conditions

Advanced Solid TumorsHER2-positive Breast CancerHealthy Participants

Phase 1

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Active, not recruitingNCT05593094

Hoffmann-La RocheAdvanced Solid Tumors, HER2-positive Breast Cancer

Start: 2020-09-03End: 2027-08-31Target: 210Updated: 2026-08-21

A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants

CompletedNCT07051993

Genentech, Inc.Healthy Participants

Start: 2025-06-27End: 2025-07-12Updated: 2025-10-16

Related Papers

Safety and efficacy of ZN-A-1041, a highly blood-brain barrier (BBB)–permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial.

Journal of Clinical Oncology2026-05-27

Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.

Journal of Clinical Oncology2023-06-013 citations